Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Pipeline Review, H2 2016’, provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted pipeline therapeutics.

The report provides comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BioApex, s.r.o.

C4X Discovery Holdings PLC

Catabasis Pharmaceuticals, Inc.

Evgen Pharma Plc

Ixchel Pharma, LLC

Jiangsu Hengrui Medicine Co., Ltd.

Reata Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

XenoPort, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Overview 9

Therapeutics Development 10

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Stage of Development 10

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Therapy Area 11

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Indication 12

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Companies 17

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Products under Development by Universities/Institutes 20

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development 29

BioApex, s.r.o. 29

C4X Discovery Holdings PLC 30

Catabasis Pharmaceuticals, Inc. 31

Evgen Pharma Plc 32

Ixchel Pharma, LLC 33

Jiangsu Hengrui Medicine Co., Ltd. 34

Reata Pharmaceuticals, Inc. 35

Rigel Pharmaceuticals, Inc. 36

XenoPort, Inc. 37

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles 38

BA-1521 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

bardoxolone methyl - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CAT-4001 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

dimethyl fumarate DR - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

IXC-101 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

IXC-103 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

LH-503 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

LH-526 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

MG-132 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

MIND-4 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

monosodium luminol - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

omaveloxolone - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

R-970 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

SFX-02 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

SFX-03 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecule to Activate Nrf2 for Inflammation - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecules to Activate NRF-2 for COPD and Multiple Sclerosis - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Activate Nrf2 for Cancer and Inflammation - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules to Activate Nrf2 for Inflammation - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Sulforadex - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

TBE-31 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

trigonelline hydrochloride - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

VEDA-1209 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

XP-23829 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Projects 78

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products 83

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Featured News & Press Releases 84

Jul 05, 2016: Bach Pharma Appoints Kelly Blackburn as Chief Executive Officer 84

Jun 23, 2016: Reata Pharmaceuticals Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension 84

May 03, 2016: Evgen Pharma: First Patient Dosed in Phase II Clinical Trial in SAH 85

Apr 18, 2016: TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness 85

Apr 12, 2016: Biogen to Present Data on TECFIDERA at 2016 AAN Annual Meeting 88

Mar 02, 2016: Approval of Phase II Clinical Trial in SAH 89

Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich’s Ataxia 90

Jan 05, 2016: Reata Enrolls First Patient with Pulmonary Hypertension Associated with Interstitial Lung Disease in LARIAT, a Phase 2 Study Examining Bardoxolone Methyl for the Treatment of Patients with Pulmonary Hypertension 90

Oct 27, 2015: Reata Announces Initial Phase 2 Pulmonary Arterial Hypertension Data for Bardoxolone Methyl and Planned Initiation of Phase 3 Study 91

Oct 23, 2015: Updated recommendations to minimize the risk of the rare brain infection PML with Tecfidera 93

Oct 07, 2015: New Data Show Strong, Sustained Effects of TECFIDERA in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients 95

Oct 01, 2015: Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, On New TECFIDERA Data Demonstrating Importance of Early Treatment 98

Sep 16, 2015: Reata to Present Initial Phase 2 Data on Bardoxolone Methyl, a Novel Experimental Therapy for Pulmonary Hypertension Used in Patients on Stable Background PAH Therapy 99

Sep 15, 2015: XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis 99

Sep 02, 2015: USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA (Dimethyl Fumarate) 101

Appendix 102

Methodology 102

Coverage 102

Secondary Research 102

Primary Research 102

Expert Panel Validation 102

Contact Us 102

Disclaimer 103

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Comparative Analysis by Unknown Stage Development, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by BioApex, s.r.o., H2 2016 29

Pipeline by C4X Discovery Holdings PLC, H2 2016 30

Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 31

Pipeline by Evgen Pharma Plc, H2 2016 32

Pipeline by Ixchel Pharma, LLC, H2 2016 33

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 34

Pipeline by Reata Pharmaceuticals, Inc., H2 2016 35

Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 36

Pipeline by XenoPort, Inc., H2 2016 37

Dormant Projects, H2 2016 78

Dormant Projects (Contd..1), H2 2016 79

Dormant Projects (Contd..2), H2 2016 80

Dormant Projects (Contd..3), H2 2016 81

Dormant Projects (Contd..4), H2 2016 82

Discontinued Products, H2 2016 83

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports